XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer


NCT00215722

Interventional

Phase 2

Unknown status
The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination. This study is aimed at establishing the efficacy and safety of the combination cetuximab/XELOX as first line therapy in patients with MCRC.
Jul 31,2005
All
18 Years
N/A
45

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.